Drug Interaction Exposures in an Intensive Care Unit: Antihypertensive Population
Muhammad Tahir Aziz, Naveed Ahmad, Taha Nazir
Department of Pharmacy, Shaukat Khanum Memorial Cancer Hospital & Research Center, Lahore, Pakistan &Saulat Institute of Pharmaceutical Sciences, Quaid-i-Azam University, Islamabad, Pakistan. Saulat Institute of Pharmaceutical Sciences, Quaid-i-Azam University, Islamabad, Pakistan.Faculty of Pharmacy, University of Sargodha, Sarogdha 40100 Pakistan
Keywords: -
Abstract

-

Article Information

Identifiers and Pagination:
Year:2015
Volume:7
First Page:41
Last Page:48
Publisher Id:19204159.7:1.2015
Article History:
Received:November 3, 2014
Accepted:November 10,2014
Collection year:2014
First Published:January 1, 2015

Introduction

Drug-drug interaction is an event that occurs when the effects of one drug modified by another drug or food when taken concurrently or concomitantly. This interaction either reduced the effect or no effect or increased drug effect [Hartshorn, 2006]. Patient in intensive care unit (ICU) are highly susceptible to drug interactions because of the complexity of the drugs regimens they receive. Drugs may affect the Pharmacokinetics of the critical ill patients and subsequently altered the pharmacological response, which potentially lead to serious adverse drug events. Drug-drug interaction (DDI) are considered predictable and thus avoidable and manageable [Cruciol-Souza et al., 2006].  

Importance of DDI in ICU:

Risk factors for drug interactions can be related to patient, drug and medical prescription. Patient-related factors include people that are more vulnerable to drug interactions such as the elderly, patients undergoing surgical procedures, those receiving intensive care, and immunosuppressed patients. The drug interactions increasein proportionate as the number of drugs prescribed increases[Ceia, 2007]. It is assessed that drug interactions occur in 3% to 5% of patients receiving a 3-6 number of drugs, and increase to 10% to 20% in patients receiving 10 to 20 drugs [Bustamante et al, 2005]. It is estimated that potential DDI occurred in 11% of admissions to the general ICU, after limiting analysis to severe and relevant DDI types. The most frequently encountered drug classes were antithrombotic agents and antibacterial for systemic use. [Askari M et al, 2013]. In one of the studies, it has been identified that the average number of drugs used per patients was nine and potential DDIs found per patient were two [S Ray et al, 2009]

Classification of Drug Interaction:

There are different methods to classify the drug interactions.One of the data bank software DRUG-REAX (Klasco RK, 2008) identifies the interactions, provides information about the associated clinical consequences or adverse reactions to drugs and characterizes the interaction mechanism. Furthermore, this database provides information about clinical consequences or adverse drug reaction (ADR) that could result from a DDI, describe the interaction mechanism and classifies onset, severity and scientific knowledge of adverse reactions caused by the DDI.

I – Classification according to the time of onset

1.       Rapid (effects expected within 24 hours of drug administration)

2.       Delayed (effects not expected to appear within the first 24 hours following drug administration)

3.       Unknown (effects expected to appear any time after drug administration).

II – Classification according to the severity

1.       Contraindicated           or ‘X’

2.       Severe                           or ‘D’

3.       Moderate                       or ‘C’

4.       mild                                or ‘B’

5.       unknown                       or ‘A’

III - Classification based upon scientific documentation categories

1.       Excellent

2.       Good

3.       Fair

4.       Poor

5.       unlikely and

6.       unknown

IV – Classification according to the mechanism

1.       Pharmacokinetic

2.       Absorption

3.       Distribution

4.       metabolism or

5.       excretion

6.       Pharmacodynamic

Table – 1 Ten Most Potential DDI in ICU [Adriano Max et al, 2011]

Commonly used drugs in ICU are vasoconstrictors and cardiotonic agents, antimicrobials, coronary vasodilators, direct vasodilators, anti-secretory drugs, anticoagulants, sedatives- hypnotics agents, anti-emetics, anti-diabetics agents, analgesics-antipyretics and anti-inflammatory drugs.Classification of DDI involving antihypertensive drugs in medical prescriptions of adult inpatients in ICU has been summarized in Table 2. 

Table 2 Classification of DDI involving antihypertensive drugs in medical prescriptions of adult inpatients in ICU

Potential DDI with Major Severity:

All DDI including details of severity and outcome has been summarized in the Table 2.  The major DDI, which constitutes a life-threatening (interaction and/or medical intervention to minimize or prevent serious adverse effects) and contraindicated DDI constituted a life-threatening interaction with high mortality rate, is discussed as follows

Calcium channel blockers + (Opioid or beta-blocker or alpha 2-adrenergic)

A severe DDI is present when calcium channel blockers combine with opioid analgesics, which is classified as majorseverity because it may result in severe hypotension and an increased risk of respiratorydepression caused by fentanyl toxicity.

For example, diltiazem HCL is a moderate CYP3A4inhibitor and fentanyl is a CYP3A4 substrate. The concurrent use may result in increasedfentanyl plasma levels and fatal respiratory depression. Caution is necessary if these agentsare givenconcurrently and use the lowest possible fentanyl dose. Patient should be carefullymonitored for an extended period of time for fentanyl adverse events. Any dosage increasesto either medication should be made carefully.

Co-administration of calcium channel blockers and beta-blocker drugs is also classified asmajor severity because it may result in an increased risk of hypotension, bradycardia,atrioventricular conduction disturbances. If concurrent therapy is required, cardiac functionand blood pressure should be carefully monitored, particularly in patients predisposed toheart failure. A dosage adjustment for hepatically metabolized beta blockers may berequired.

The combination of calcium channel blockers with alpha 2-adrenergic agonistic drug isalso classified as major severity because it may result in increased incidence of sinus bradycardiarequiring hospitalization and insertion of a pacemaker. Therefore, heart rate should bemonitored when clonidine and verapamil or diltiazem are given concurrently.

Beta-blocker + sympathomimetic drugs

The concomitantuse of beta-blocker and sympathomimetic drugs should be evaded because it may result in hypertension, bradycardia and resistance to epinephrine in anaphylaxis. But, if concomitant therapy is necessary, patient should be carefully monitored for severe and prolonged hypertension.

Alpha 2-adrenergic blockers + beta-blockers

Alpha 2-adrenergic blockers and beta-blockers may result in increased risk of sinus bradycardia and exaggerated clonidine withdrawal response. Monitor heart rate when clonidine and atenolol are given concurrently. Patients to be withdrawn from clonidine who are concomitantly receiving a beta blocking agent, such as atenolol, should be withdrawn from the beta blocker several days before the gradual discontinuation of clonidine to avoid an excessive rise in blood pressure. In the case of a hypertensive crisis following discontinuation of clonidine, IV phentolamine or oral clonidine can be used to reverse the excessive rise in blood pressure. Patients to be withdrawn from clonidine who are concomitantly receiving a beta blocking agent should be monitored carefully for hypertension.

Antihypertensive and anti-inflammatory agents

NSAIDmay block the antihypertensive effects of thiazide and loop diuretics, ß-adrenergic blockers, a-adrenergic blockers and angiotensin converting enzyme inhibitors. It seems to happen by NSAID interference with prostaglandins synthesis which may thus limit the ability of antihypertensive drugs to control blood pressure. When concomitant use of loop diuretics and NSAID is required, patient should be monitored for diuretic efficacy and for signs of renal failure.

Factors associated with the occurrence of potential DDI in the ICU:

It has been identified that only inducers of cytochrome P450, drugs that prolong the QT interval and drugs from group C of the ATC (cardiovascular system) were significantly associated with potential DDIs. In the first 24 hours in ICU, a potential DDI correlation discovered between drugs with a narrow therapeutic index and drugs from ATC group N. At the time of discharge, inhibitors of cytochrome P450, drugs that affect glycoprotein P and drugs from groups J and L were significantly correlated with potential DDIs [Adriano Max et al, 2011].

Table 3 - Factors associated with the occurrence of potential DIs in the ICU [Adriano Max et al, 2011]

ND - not determined because every Patient in the study used at least one medication of this ATC Group. CI-Confidence interval

1: Chi-square test with Yates correction; 2: Chi-square test; 3: Fisher's exact test. OR - adds ratio

The administration of drugs with a narrow therapeutic index was an important factor of DDIs. The pharmacotherapy of critically ill patients requires the use of cyclosporine, phenytoin, vancomycin and digoxin, in addition to other drugs with narrow therapeutic indexes. The identified association was likely due to the use of these drugs.

A strong association in terms of DDI has been discovered between drugs that prolong the QT interval and there is a growing concern regarding these drugs due to the risk of cardiotoxicity with cardiac events. [Letsas et al, 2009]. These adverse events can be determined by potential pharmacokinetic interactions that inhibit the metabolism of drugs with this property or by pharmacodynamic synergism. The metronidazol+amidorane, amiodarone+haloperidol etc. interactions detected, which can produce the potential adverse events.

Management of DDI in ICU:

There are many potential DDIs with high alleged relevance in the ICU that appear to require attention and follow-up. Different strategies can be adopted to manage the DDI in the ICU

1.       Depute one dedicated Clinical Pharmacist to review the medication system in ICU

2.       Prescription verification and validation should be mandatory

3.       Patient Care Plan

4.       All drugs should be dispensed after pharmacist verification

5.       Patient Labs., organ system must be reviewed before initiation of any new therapy

6.       Medication monitoring

7.       Continuous liaison with the physician 

8.       Computerized decision support system may help reduce the number of potential DDIs but needs to be accustomed to the environment in which it operates.

CONCLUSION:

DDIs are common in the ICU population in the presence of poly-pharmacy, and a considerable proportion of drugs are clinically relevant. Critically ill patients may also augment an intended pharmacologic response and potentially result in an unintended effect.A team approach is important to identify, prevent, and address drug interactions in the intensive care setting and optimize patient outcomes. Additionally, a clinical decision support system is an important toll to identify potential interactions in the prescription and reduce the adverse drug events. The peer review meeting between the healthcare professional involved in prescribing, dispensing and administering the drugs are the main domain of risk factors, the education and updates regarding the most frequent and potential drug interactions an also help in the prevention of drug interactions.

REFERENCES:

1.       Askari M et al, ‘Frequency and nature of drug-drug interactions in the intensive care unit’, Drug Saf, 2013 Apr; 22(4):430-7

2.       Cruciol-Souza, JM; Thomson ,JC&Catisti, DG. (2008). Avaliação de prescriçõesmedicamentosas de um hospital universitáriobrasileiro. Revistabrasileiraeducaçãomédica.v. 32, n.2, p.188–196, ISSN 0100-5502.

3.       Hartshorn EA. Drug Interaction. Ann Pharmacother 2006; 40(1):112-3

4.       Ceia, F. Interacçõesmedicamentosasnapráticaclínica. Rev Port ClinGeral 2007; 23:197-207.

5.       Bustamante GDD, Cabrera C, Duran GMG, Nunez MTJ. Detección de interaccionesmedicamentosas, empacientesingresados a la unidad de cuidadosintensivosdelInstitutoAutônomo Hospital Universitário de los Andes. Vitae Academia BiomédicaDigita 2005; 25(7):1-16.

6.       S Ray et al, rug–drug interactions in the ICU, Critical Care 2009, 13(Suppl 1):P495

7.       Goldberg RM, Mabee J, Chan L, Wong S. Drug-drug and drug- disease interactions in the ED: Analysis of a high-risk population. J. Emerg. Méd 1996; 14 (5):447-50.

8.       Egger SS, Drewe J, Schlienger RG. Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur J ClinPharmacol 2003; 58(11):773-7.  

9.       Klasco RK, Moore RE. Drug Reax®.GreenwoldVillage(CO): Micromedex; 2008.

10.    Adriano Max et al,’ Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil’, Clinics (Sao Paulo). Jan 2011; 66(1): 9–15.

11.  Letsas KP, Efremidis M, Kounas SP, Pappas LK, Gavrielatos G, Alexanian IP, et al. Clinical characteristics of patients with drug-induced QT interval prolongation and torsade de pointes: identification of risk factors. Clin Res Cardiol. 2009;98:208–12.


© 2016 The Author(s). This open access article is distributed under a Creative Commons Attribution (CC-BY) 4.0 license. You are free to: Share — copy and redistribute the material in any medium or format Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. No additional restrictions You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits
Editor in Chief
Prof. Dr. Cornelia M. Keck (Philipps-Universität Marburg)
Marburg, Germany

Bibliography

Welcome to the research group of Prof. Dr. Cornelia M. Keck in Marburg. Cornelia M. Keck is a pharmacist and obtained her PhD in 2006 from the Freie Universität (FU) in Berlin. In 2009 she was appointed as Adjunct Professor for Pharmaceutical and Nutritional Nanotechnology at the University Putra Malaysia (UPM) and in 2011 she obtained her Venia legendi (Habilitation) at the Freie Universität Berlin and was appointed as a Professor for Pharmacology and Pharmaceutics at the University of Applied Sciences Kaiserslautern. Since 2016 she is Professor of Pharmaceutics and Biopharmaceutics at the Philipps-Universität Marburg. Her field of research is the development and characterization of innovative nanocarriers for improved delivery of poorly soluble actives for healthcare and cosmetics. Prof. Keck is executive board member of the German Association of Nanotechnology (Deutscher Verband Nanotechnologie), Vize-chairman of the unit „Dermocosmetics“ at the German Society of Dermopharmacy, active member in many pharmaceutical societies and member of the BfR Committee for Cosmetics at the Federal Institute for Risk Assessment (BfR).

Journal Highlights

Subject & Scope
  • Pharmaceutics
  • Physical Pharmacy 
  • Dosage Forms Science 
  • Pharmaceutical Microbiology & Immunology 
  • Industrial Pharmacy 
  • Bio-Pharmaceutics 
  • Pharmaceutical Chemistry 
  • Pharmaceutical Instrumentation 
  • Medicinal Chemistry 
  • Pharmacognosy 
  • Physiology &Histology 
  • Anatomy & Pathology 
  • Pharmacology & Therapeutics 
  • Pharmacy Practice 
  • Pharmaceutical Mathematics   
  • Biostatistics 
  • Dispensing 
  • Community Social & Administrative Pharmacy 
  • Hospital Pharmacy 
  • Clinical Pharmacy 
  • Pharmaceutical Quality Management 
  • Forensic Pharmacy 
  • Pharmaceutical Technology 
  • Pharmaceutical Management & Marketing

Consortium Publisher is an online publisher that enjoys global presence with International Journals

Follow Us

©2009 - 2019 Consortium Publisher Canada

Contact Info

6252 Lisgar Dr Mississauga Ontario L5N7V2 Canada
+1 (647) 526-0885
office@consortiumpublisher.ca
http://www.consortiumpublisher.ca/